Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer
Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.
Most recent update: Jun 2024
Source: Statista Market Insights
Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.
Most recent update: Mar 2024
The demand for Anti-Fibrinolytic Drugs in the Baltics has been on the rise in recent years.
Customer preferences: Patients in the Baltics are showing a growing preference for Anti-Fibrinolytic Drugs due to their effectiveness in reducing bleeding during surgical procedures. As a result, hospitals and clinics are increasingly prescribing these drugs to patients undergoing surgeries.
Trends in the market: The Anti-Fibrinolytic Drugs market in the Baltics is being driven by the increasing number of surgical procedures being performed in the region. Additionally, the growing awareness about the benefits of these drugs among patients and healthcare professionals is also contributing to the growth of the market.
Local special circumstances: The Baltics region is witnessing a rise in medical tourism, with an increasing number of patients from neighboring countries traveling to the region for medical treatment. This is also contributing to the growth of the Anti-Fibrinolytic Drugs market in the region.
Underlying macroeconomic factors: The Baltics region is experiencing a stable economic growth, which is leading to an increase in healthcare spending. Additionally, the region's aging population is also contributing to the growth of the Anti-Fibrinolytic Drugs market as older individuals are more likely to require surgical procedures that require these drugs.
Most recent update: Jun 2024
Source: Statista Market Insights
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Notes: Based on data from IMF, World Bank, UN and Eurostat
Most recent update: Sep 2024
Source: Statista Market Insights